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A B S T R A C T
Purpose: To describe an atypical presentation of Tubulointerstitial Nephritis and Uveitis (TINU), with challenges
in treatment course.
Observations: A 12-year-old Hispanic female presented to the National Eye Institute's Uveitis clinic with bilateral
blurred vision, red eyes and photophobia, not responsive to topical steroids. On exam, she had bilateral severe
panuveitis with areas of subretinal fluid. During her evaluation, she was noted to have elevated serum creati-
nine. A kidney biopsy confirmed the presence of severe tubulointerstitial nephritis and interstitial fibrosis. She
was treated with oral steroids with excellent resolution of symptoms and subretinal fluid. She continued to have
anterior segment flares with attempts to taper oral prednisone which lead to treatment with multiple im-
munomodulatory agents. Associated hypertension and kidney damage complicated the choice of a secondary
immunosuppressive agent.
Conclusions and Importance: Although rare, TINU can present as panuveitis with choroidal involvement which
may or may not be preceded by tubulointerstitial nephritis. A renal biopsy is required for definitive diagnosis,
but abnormal urinalysis or renal function should raise suspicion for TINU.
1. Introduction
Tubulointerstitial Nephritis and Uveitis (TINU) is a rare disease with
an estimated prevalence of 0.1%–2.3% of uveitis diagnoses; though it is
speculated that this is an underestimation due to the multisystem
nature of the clinical presentation precluding prompt diagnosis.1 TINU
was classically characterized in the literature as a disease that affected
females (3:1) presenting in adolescence (age range 9–74 years).2
However, recent evidence suggests that there is no sex difference.3–5
While often idiopathic in etiology, drugs such as non-steroidal anti-in-
flammatory drugs and certain antibiotics are implicated as a cause of
TINU.2,6
TINU is typically characterized by acute onset, bilateral, non-gran-
ulomatous, mild anterior uveitis accompanied by tubulointerstitial ne-
phritis, however there have been sporadic reports of TINU presenting
with posterior uveitis.6,7 Complications of TINU can include posterior
synechiae, optic disc swelling and cystoid macular edema. TINU is
generally self-limiting, but recurrences have been documented.2,4,8
While recurrences of uveitis tend to be rarer in younger patients, they
are more likely to progress to chronic uveitis than older patients.2
There are several systemic diseases that have both renal and uveal
involvement and can therefore appear clinically similar to TINU, such
as: Sarcoidosis, Behcet's disease, Sjogren's disease, Granulomatosis with
polyangiitis, Systemic Lupus Erythematosus and IgA nephropathy.2 In
TINU, the uveitis can precede, or coincide with the interstitial ne-
phritis.3The inconsistency of presentation timeline among cases can
compound the diagnostic difficulty. We present a challenging and
atypical case of TINU in a young Hispanic female with a history con-
cerning for Lyme associated uveitis due to positive IgM, a clinical ap-
pearance suggestive of VKH due to exudative detachment and a poor
response to standard of care treatment with oral corticosteroid and
immunosuppressant medications. We elaborate upon the diagnostic
dilemma and multidisciplinary team decision making that helped elu-
cidate the etiology and frame the management.
2. Case history
A 12-year-old Hispanic female and recent immigrant from
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Guatemala presented with a three-month history of bilateral uveitis
unresponsive to topical steroids. Outside workup for infectious and
inflammatory etiology revealed elevated ESR (98 mm/hour) and a
positive Lyme serology (23 kDa IgM on Western Blot), despite the fact
that the patient had no history of hiking or camping in an endemic area
and no history of targetoid rash. The patient was treated with oral
doxycycline for 2 months with presumed diagnosis of Lyme associated
uveitis with no improvement of ocular inflammation and was referred
to our uveitis service for presumed treatment-resistant Lyme uveitis.
Her principal complaint was blurry vision and severe headaches for
which she was self-medicating with over the counter Ibuprofen several
times daily. On examination, she was afebrile, with normal blood
pressure (110/75 mmHg). Her best corrected visual acuity (BCVA) was
20/40 in the right eye and 20/32 in the left eye. The anterior chamber
showed 3 + cells and 1 + flare bilaterally. There was 2 + cell and
1 + haze in the vitreous of the right eye and trace cell with no haze in
the left eye. Fundus exam showed bilateral asymmetric disc edema and
multiple areas of subretinal fluid in the left eye and hypocyanescent
choroidal lesions in both eyes on Indocyanine Green Angiography
(ICG), suggestive of choroidal inflammation (Figs. 1–2).
An extensive laboratory workup showed: normoglycemic glycosuria
and proteinuria on urinalysis; elevated serum beta-2 microglobulin (4.6
mg/L, normal range [0.9–1.7 mg/L]); ESR within normal limits (28
mm/hr); negative autoimmune antibody panel (ANA, anti-dsDNA, RF,
anti-CCP); Lyme as well as Syphilis, Tuberculosis, Bartonella henselae,
Toxoplasmosis and Borrelia studies were all negative. HLA typing in-
dicated HLA A2,33; B15,51, C14,5, DRB1 01,08, DQB1 04,05.
Neurology was consulted due to the presence of bilateral disc edema.
Opening pressure on lumbar puncture was within normal limits, CSF
ELISA and WB were negative for Lyme, and MRI of the orbit and sur-
rounding structures revealed no abnormalities. Review of the patient's
previous labs, as ordered by the referring clinician, showed a creatinine
of 3.6 mg/dL, however, at presentation to us it was lower at 1.9 mg/dL,
though still abnormal.
Clinical evaluation and laboratory work up suggested a differential
diagnosis of incomplete Vogt-Koyanagi-Harada syndrome (VKH) with
NSAID overuse that contributed to the elevated serum creatinine versus
TINU. The patient began a course of oral and topical corticosteroids
which resulted in complete resolution of the disc edema and subretinal
fluid. Her serum creatinine continued to trend downward with treat-
ment to 1.3 mg/dL.
Given the presence of persistently elevated creatine and elevated
beta-2 microglobulin, a kidney biopsy was performed that showed se-
vere tubulointerstitial fibrosis with tubular atrophy. There was a dense
lymphomononuclear interstitial infiltrate composed of small mature
lymphocytes admixed with occasional plasma cells with glomerular
sparing. No significant eosinophilic component was present. The kidney
biopsy was negative for both viral inclusions and interstitial granu-
lomas (Fig. 3). The results confirmed TINU as the diagnosis, and she
was restarted on high dose oral prednisone and mycophenolate mofetil.
However, she continued to have anterior chamber flares at lower doses
of prednisone (< 20mg/day), requiring addition of another im-
munosuppressive agent. In addition, her serum creatinine continued to
increase to a level of 2.3 mg/dl.
A multidisciplinary team consisting of a uveitis specialist, pediatric
nephrologist and pediatric rheumatologist were involved in her care to
determine the best treatment course. The patient's hypertension and
kidney damage limited use of cyclosporin A; addition of an anti-
metabolite (mycophenolate mofetil) as corticosteroid-sparing agent
resulted in insufficient response and the use of biologics are seldom
reported in the management of TINU.9 The multidisciplinary team
consensus was to begin subcutaneous adalimumab 40mg every 2 weeks.
This led to an improvement in the serum creatinine to 1.3 mg/dL al-
lowing the patient to slowly taper her oral prednisone dose while re-
maining on mycophenolate mofetil. She has remained quiet in both
eyes. Her serum creatinine has remained at a stable level of 1.3mg/dL
(normal range 0.67–1.17 mg/dL) suggesting chronic irreversible mild
kidney damage.
Fig. 1. Right Eye at Presentation.
A. Macula Optical Coherence Tomography (OCT) demonstrates normal foveal contour and thickness. Nasal disc edema can also be noted. B. Infrared imaging (IR) of the optic nerve shows
360-degree disc edema. C. Indocyanine green (ICG) angiography at 5 minutes shows multiple hypocyanescent spots in the choroid. D. Fluorescein angiography (FA) at 10 minutes shows
leakage from the optic disc.
S. Caplash et al. American Journal of Ophthalmology Case Reports 10 (2018) 253–256
254
3. Discussion
This atypical case of TINU presents several relevant teaching points
to the current practice of uveitis. The history began with the tentative
diagnosis of Lyme-associated uveitis. The diagnosis was based on the
presence of 1 band of IgM for Lyme (23kD). The patient's history lacked
definitive evidence of a tick bite and the typical targetoid rash. As per
the Centers for Disease Control (CDC), a positive IgM Lyme Serology
requires the presence of two of the following three bands: 24 kDa, 39
kDa & 41 kDa. Relying on the presence of only one IgM band does not
indicate a positive Lyme serology, though it can occur very early after
the exposure and needs to be confirmed with repeat testing in 6 weeks.
In addition, presumed Lyme disease with ocular involvement is con-
cerning for neuro-Lyme disease. Treatment regimen as per CDC
guidelines for neurologic Lyme consists of one dose of 50–75 mg/kg
intravenous ceftriaxone. Therefore, even under a presumed Lyme as-
sociated uveitis diagnosis, treatment with oral doxycycline is not re-
commended.10This underscores the importance of strict attention to
specific CDC guidelines regarding Lyme diagnosis and treatment.11–13
The clinical appearance of our patient on exam was characterized by
diffuse choroiditis and multiple exudative retinal detachments, differ-
entiating this case from typical cases of TINU. Neither posterior in-
volvement nor serous retinal detachments are common features of
TINU, however, there have been few reports of TINU presenting with
Fig. 2. Left Eye at Presentation.
A. Macula OCT demonstrates normal foveal contour and thickness and multiple pockets of subretinal fluid. B. IR of optic nerve shows disc edema superiorly. C. ICG at 5 minutes shows
multiple hypocyanescent spots in the choroid. D. FA at 10 minutes shows leakage from the optic disc and pinpoint areas of fluorescein leakage and pooling.
Fig. 3. Kidney Biopsy showing Tubulointerstitial
Inflammation.
Hematoxylin & Eosin stained native kidney biopsy re-
vealing no significant proliferative, sclerosing or necro-
tizing lesions in the glomeruli. The main abnormalities in-
clude a patchy dense interstitial lymphomononuclear
infiltrate; predominantly composed of small mature lym-
phocytes admixed with occasional plasma cells. No sig-
nificant eosinophilic component or granulomatous in-
flammation is seen. Trichrome staining reveals severe
chronic tubulointerstitial disease with tubular atrophy and
interstitial fibrosis (blue). Blood vessels are mildly thick-
ened and with no vasculitis. (For interpretation of the re-
ferences to colour in this figure legend, the reader is re-
ferred to the Web version of this article.)
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posterior uveitis.6,7,14,15 Our patient's clinical exam findings were in-
itially suggestive of Vogt-Koyanagi-Harada disease, a multi-system au-
toimmune disease affecting the visual, integumentary, nervous and
auditory systems that commonly affects persons of Asian, Latin or Na-
tive American descent. However, the patient did not meet full diag-
nostic criteria as no extraocular manifestations were observed. In con-
junction with these findings, the chronic inflammation with anterior
uveitis exacerbations during steroid taper further supported a possible/
presumed diagnosis of incomplete VKH.16–19
However, the elevated serum creatinine and elevated urine Beta2
microglobulin did not fit with the diagnosis of VKH and implicated a
possible systemic or concurrent pathology impacting renal function.
Our differential diagnoses to explain these lab values included IgA
nephropathy and TINU, as elevated urinary b2 microglobulin is a cri-
tical lab test for suspected TINU.5 However, after patient history re-
vealed she had been taking 600mg (11 mg/kg) of Ibuprofen six times a
day for headache relief, NSAID associated acute tubular necrosis versus
NSAID associated tubulointerstitial nephritis were also included in the
differential. The recommended pediatric dosing for Ibuprofen is 10 mg/
kg every 6–8 hours, and she well exceeded this dosing. NSAID overuse
can cause pre-renal azotemia with minimal histopathologic changes;
acute interstitial nephritis, characterized by tubular edema and inter-
stitial inflammation which may be accompanied by proteinuria. Lastly,
NSAID use can cause nephrotic syndrome (mainly membranous glo-
merulopathy or minimal change disease20).
A definitive diagnosis of TINU was confirmed by kidney biopsy. In
contrast to the above renal pathologies, the kidney biopsy findings in
TINU shows tubulointerstitial edema and a lymphocytic infiltrate that is
distinctly different from the glomerular presentation of: Minimal
Change Disease, Membranous Nephropathy and IgA-Nephropathy.
TINU is typically responsive to oral corticosteroids. However, pa-
tients can have relapses of either their renal disease or uveitis when
followed long term.3 Our patient responded well to oral corticosteroids,
however we were unable to taper her below 10 mg daily. The addition
of mycophenolate mofetil did not help with control of ocular in-
flammation, leading to a debate regarding which second agent was
most suited for her long-term care. Adalimumab (Humira®) is currently
indicated in the treatment of non-infectious intermediate, posterior and
panuveitis in adult patients. Adalimumab is typically given in a range of
doses between 20 mg–40 mg subcutaneously, biweekly; most com-
monly in conjunction with other medications, such as mycophenolate
mofetil or methotrexate.21 Use of adalimumab in pediatric population is
limited to Juvenile Idiopathic Arthritis (JIA) associated uveitis and
Crohn's disease. Small studies have shown that adalimumab is a rela-
tively safe and effective treatment in pediatric uveitis.21,22 However,
adalimumab is not an archetypal choice of immunosuppressive agent
for TINU.
An extensive discussion between all members of the multi-
disciplinary team and the family was performed to explain the limited
evidence based knowledge and long-term safety data of biologics for
TINU. However, given her recalcitrant inflammation and the lack of
other suitable immunosuppressive agents, adalimumab was considered
the best option at the time.
This case highlights the need for judicious attention to the non-
ocular symptoms and laboratory assessments of patients with uveitis. It
also stresses the need for a multidisciplinary team to elucidate an
etiology and management plan for these rare multifactorial causes of
ocular inflammation, as well as to provide holistic treatment and avoid
chronic systemic damage.
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